Insulin detemir: A long-acting insulin product

American Journal of Health-System Pharmacy

Volumn 63, Issue 24, 2006, Pages 2466-2472

  Jones, Melissa C ^a,b   Patel, Mallika ^b  

^a U of WI School of Pharmacy   (United States)

^b SOUTHERN UNIVERSITY   (United States)

Author keywords

Binding; Costs; Diabetes mellitus; Dosage; Drug administration; Drug interactions; Duration of action; Insulin detemir; Insulins; Pharmacokinetics; Sustained action medications; Toxicity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CORTICOSTEROID; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HEPARIN; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN; PHENYLBUTAZONE; VALPROIC ACID; WARFARIN;

ALLERGIC REACTION; BODY WEIGHT; BOLUS INJECTION; CLINICAL TRIAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE NODULE; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 33847772362     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060102     Document Type: Review

References (26)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
2. American Diabetes Association. Position statement: standards of medical care in diabetes-2006. Diabetes Care. 2006; 29(suppl 1):S4-42.
3. Hordern SV, Russell-Jones DL. Insulin detemir, does a new century bring a better insulin? Int J Clin Pract. 2005; 59:730-9.
4. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care. 1999; 22(suppl 2):B109-13.
5. Rosenstock J, Riddle M. Treatment to target in type 2 diabetes: consistent risk reduction of hypoglycaemia with basal insulin glargine as compared with NPH insulin in insulin-naive patients on oral agents. Diabetologia. 2002; 45(suppl 2):805. Abstract.
6. Novo Nordisk. Levemir product information. www.levemir-us.com/ prescribing_information.pdf (accessed 2006 Jan 22).
7. Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2004; 64:2577-95.
8. Goldman-Levine J, Lee KW. Insulin detemir-a new basal insulin analog. Ann Pharmacother. 2005; 39:502-7.
9. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53:1614-20.
10. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes. 2004; 28(suppl 2): S23-8.
11. Mathieu C. Can we reduce hypoglycemia with insulin detemir? Int J Obes. 2004; 28(suppl 2):S35-40.
12. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005; 7:56-64.
13. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003; 26:590-6.
14. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care. 2004; 27:1081-7.
15. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005; 7:73-82.
16. Hermansen K, Fontaine P, Kukolja K et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type I diabetes. Diabetologia. 2004; 47:622-9.
17. Pieber TR, Draeger E, Kristensen A et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005; 22:850-7.
18. Raslova K, Bogoev M, Raz I et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004; 66:193-201.
19. Standl E, Lang H, Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther. 2004; 6:579-88.
20. Russell-Jones D. Insulin detemir: improving the predictability of glycaemic control. Int J Obes Relat Metab Disord. 2004; 28(suppl 2):S29-34.
21. Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord. 2004; 28(suppl 2):S41-6.
22. Hermansen K, Madsbad S, Perrild H et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in Type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001; 24:296-301.
23. Darmon P, Castera V, Koeppel M et al. Type III allergy to insulin detemir. Diabetes Care. 2005; 28:2980. Letter.
24. Novo Nordisk. Levemir treatment guidelines. www.novonordisk.com/ diabetes/hcp/pharmaceuticals/Levemir/ treatmentguidelines.asp (accessed 2006 Feb 14).
25. Micromedex. Healthcare Series. Vol. 127. Drugdex evaluation. Insulin detemir (1.2). Greenwood Village, CO: Thomson Micromedex; 2006.
26. Drugstore.com. www.drugstore.com. (accessed 2006 Oct 3).